CClinicalTrials.gg
CompletedNCT03273166Updated Oct 26, 2020Results posted

Comparison of Rainbow INVSENSOR00001 and Control SpHb Disposable Sensor Performance During Hemodilution

An interventional study of INVSENSOR00001 and Control SpHb sensor in Healthy, sponsored by Masimo Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-26.

Sponsored by Masimo Corporation · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study involves comparison of the performance of two SpHb sensors in subjects that undergo a hemodilution procedure. The sensors' performance will be assessed by comparison of the measured hemoglobin values against reference values obtained by a laboratory hematology analyzer. Blood samples will be collected from healthy volunteers who undergo a hemodilution procedure wherein blood is repeatedly sampled as the concentration of hemoglobin is reduced by administering intravenous fluids to the volunteer in a controlled manner.

02

Conditions studied

  • Healthy
03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Competent adults between the ages of 18 and 50 years of age
  • Must weigh a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall
  • BMI ≤ 35 unless the physician determines that a higher BMI is not due to morbid obesity, to safeguard subject safety during hemodilution
  • Must have a hemoglobin value ≥ 11 g/dL at time of screening, to safeguard subject safety during hemodilution
  • Baseline heart rate between 45 bpm and 85 bpm
  • CO value less than 2.0% FCOHb
  • Physical status of ASA I or II (American Society of Anesthesiology Class I; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease) The ASA definition strictly applies to the systemic disease portion of the classification
  • Systolic BP less than or equal to 140 mmHg and Diastolic BP less than or equal to 90 mmHg
  • Able to read and communicate in English

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or positive hCG test
  • Smokers (including e-cigarette users)
  • Subject has known drug or alcohol abuse. Subjects who uses recreational drugs
  • Subject has experienced a concussion or head injury with loss of consciousness within the last year
  • Any chronic bleeding disorders (i.e. hemophilia)
  • Any history of a stroke, myocardial infarction, or seizures
  • Any cancer or history of cancer (not including skin cancer)
  • Chronic neurological diseases (i.e. multiple sclerosis, Huntington's Disease)
  • Any cardiac dysrhythmias (i.e. atrial fibrillation)(without physicians clearance)
  • Subject has known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder) that interferes with the subject's level of consciousness
  • Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome
  • Subjects who have/are currently taking anticoagulant medication
  • Subjects who have taken opioid pain medication within 24 hours of start of study
  • Subjects who do not understand the study and the risks
  • Subjects having either signs or history of peripheral ischemia
  • Subjects who have had invasive surgery within the past year- including but not limited to major dental surgery, gallbladder, heart, appendix, major fracture repairs (involving plates/ screws), jaw surgery, urinary tract surgery, plastic surgery, major ENT surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery
  • Subjects that have symptoms of congestion, head colds, flu, or other illnesses
  • Subjects with claustrophobia, or generalized anxiety disorder
  • Subjects who have been in severe car accident(s) or a similar type of accident(s) requiring hospitalization within the last 12 months
  • Subjects with chronic unresolved asthma, lung disease and respiratory disease
  • Subjects with allergies to lidocaine, latex, adhesives, or plastic
  • Subjects with heart conditions, insulin-dependent diabetes or uncontrolled hypertension
  • Subjects who have given vaginal delivery, had a pregnancy terminated, a miscarriage with hospitalization or had a c-section within the last 6 months
  • Subjects who intend on participating in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours following a study involving an arterial blood draw and/or arterial line placement
  • Subject has any medical condition which in the judgment of the investigator and/or medical staff, renders them ineligible for participation in this study (Discretion of investigator)
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    INVSENSOR00001 sensor

    This is a nonrandomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.

    Device: INVSENSOR00001 · Device: Control SpHb sensor · Procedure: Hemodilution

Interventions

  • DeviceINVSENSOR00001

    This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.

  • DeviceControl SpHb sensor

    This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.

  • ProcedureHemodilution

    This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers while undergoing a hemodilution procedure.

05

What researchers measure

Primary outcomes

  1. Comparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation

    Performance of the sensors will be determined by comparing the noninvasive hemoglobin measurement (SpHb) of the pulse oximeter sensors to the hemoglobin value obtained from a reference blood sample and calculating the accuracy root mean square(ARMS) value.

    Time frame: 1-5 hours

06

Results

Posted Oct 26, 2020

Participant flow

Participant flow — Overall Study
MilestoneINVSENSOR00001
Started82
Completed51
Not completed31
Withdrew: Withdrawn prior to completion31

Outcome measures

PrimaryComparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation

Performance of the sensors will be determined by comparing the noninvasive hemoglobin measurement (SpHb) of the pulse oximeter sensors to the hemoglobin value obtained from a reference blood sample and calculating the accuracy root mean square(ARMS) value.

Time frame:
1-5 hours
Reported as:
Number · g/dL
Comparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation
g/dLINVSENSOR00001Control SpHb Sensor
Comparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation0.90.9

Adverse events

Collected over 1 to 5 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INVSENSOR000010/51 (0%)0/51 (0%)2/51 (3.9%)
Most frequent other events
Most frequent other events
EventINVSENSOR00001
DizzinessInjury, poisoning and procedural complications1/51
Irregular EKG readingsInjury, poisoning and procedural complications1/51

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)INVSENSOR00001
<=18 years1
Between 18 and 65 years50
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)INVSENSOR00001
Female16
Male35
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)INVSENSOR00001
Race/Ethnicity, Customized — Caucasian17
Race/Ethnicity, Customized — Hispanic16
Race/Ethnicity, Customized — Asian or Pacific Islander3
Race/Ethnicity, Customized — Native American2
Race/Ethnicity, Customized — Black or African American13
Race/Ethnicity, Customized — Other0
07

Study locations

1 site
  • Masimo Clinical Lab
    Irvine, California 92618, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · May 8, 2018

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03273166
Lead sponsor
Masimo Corporation
Responsible party
Sponsor
First posted
Sep 6, 2017
Start date
Aug 29, 2017
Primary completion
Sep 18, 2017
Completion
Sep 18, 2017
Results posted
Oct 26, 2020
Last update
Oct 26, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion